Benchmark Investment Advisors LLC Abb Vie Inc. Transaction History

Benchmark Investment Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$159.82 - $182.1 $735,651 - $838,206	-4,603 Closed	0 $0
Q4 2023 May 15, 2024	SELL	$137.6 - $154.97 $796,428 - $896,966	-5,788 Reduced 55.7%	4,603 $713,000
Q4 2023 Feb 13, 2024	BUY	$137.6 - $154.97 $786,934 - $886,273	5,719 Added 122.41%	10,391 $1.61 Million
Q3 2023 Nov 14, 2023	SELL	$133.59 - $154.65 $111,681 - $129,287	-836 Reduced 15.18%	4,672 $696,000
Q2 2023 Aug 11, 2023	BUY	$132.51 - $164.9 $250,178 - $311,331	1,888 Added 52.15%	5,508 $742,000
Q1 2023 May 12, 2023	SELL	$144.61 - $166.54 $81,126 - $93,428	-561 Reduced 13.42%	3,620 $576,000
Q4 2022 Feb 21, 2023	BUY	$138.31 - $165.87 $53,664 - $64,357	388 Added 10.23%	4,181 $676,000
Q3 2022 Nov 14, 2022	SELL	$134.21 - $153.93 $183,330 - $210,268	-1,366 Reduced 26.48%	3,793 $509,000
Q2 2022 Aug 08, 2022	BUY	$137.62 - $174.96 $256,661 - $326,300	1,865 Added 56.62%	5,159 $790,000
Q1 2022 May 16, 2022	BUY	$131.98 - $163.75 $434,742 - $539,392	3,294 New	3,294 $534,000

3,870

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $301B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Benchmark Investment Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Benchmark Investment Advisors LLC with notifications on news.